JESSICA CHENG: Open Payments
NPI 1366002669 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$924 in 64 payments from 7 companies in 2025. Trend: 2023 $527 · 2024 $894 · 2025 $924
Food & beverage: $924
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 51 | $544 |
| Janssen Biotech, Inc. | 2 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $86 |
| Eisai Inc. | 3 | $85 |
| PFIZER INC. | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $30 |
Products named: CABOMETYX, Lenvima, RYBREVANT, Nubeqa, XTANDI, Xofigo, PLUVICTO, LYNPARZA.
Industry payments across TX — which companies pay providers there.
